CytomX Therapeutics Announces CX-072 Clinical Presentations at 2018 SITC Annual Meeting
PROCLAIM-CX-072 Clinical Translational Data Presented as Poster and Rapid-Fire Oral Presentation
Company to Host Analyst and Investor Event and Webcast
Poster P87: Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2a Trial
Presenter: | Luc Desnoyers, Ph.D., Senior Director of Translational Sciences, CytomX Therapeutics |
Date/Time: | November 9, 2018; 8:00 – 9:00 a.m. /12:45 – 2:45 p.m. /6:30 – 8:00 p.m. EST |
Location: | Poster Hall E, Walter E. Washington Convention Center |
Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2a Trial
Presenter: | Luc Desnoyers, Ph.D., Senior Director of Translational Sciences, CytomX Therapeutics |
Session: | Rapid Oral Abstracts |
Date/ Time: | November 10, 2018; 1:05 - 1:10 p.m. EST |
Location: | Poster Hall E, Walter E. Washington Convention Center |
Analyst and Investor Event and Webcast
CytomX will host an Analyst and Investor event on
For analysts and investors interested in attending the event in person, please contact ckeenan@cytomx.com as space is limited.
About
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy of CytomX’s or any of its collaborative partners’ product candidates, administered separately or in combination, CytomX’s ability and the ability of its collaborative partners to develop and advance product candidates into and successfully complete clinical trials, including CytomX’s Phase 1/2 clinical trials of CX-072, CX-2009 and CX-2029, the timing of any future clinical trials to be initiated by CytomX or any of its collaborative partners, CytomX’s expectations regarding the availability of clinical data, CytomX’s expectations with respect to its collaborations, and CytomX’s expectations regarding the timing of potential regulatory filings. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: three of CytomX’s product candidates under its Probody platform are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; CytomX’s dependence on the success of CX-072, CX-2009 and CX-2029; CytomX’s reliance on third parties for the manufacture of the company’s product candidates; and possible regulatory developments in
Contact:
Investors and Media:
VP, Investor Relations and Corporate Communications
650-383-0823
Source: CytomX Therapeutics Inc.